A more sensitive way to detect circulating tumor cells

November 18, 2020

Breast cancer is the most frequently diagnosed cancer in women, and metastasis from the breast to other areas of the body is the leading cause of death in these patients. Detecting circulating tumor cells (CTCs) in the bloodstream could help doctors find and treat metastases at an earlier stage, increasing chances of survival. Now, researchers reporting in ACS Sensors have developed a method that could more sensitively detect CTCs within the complex environment of blood.

CTCs are tumor cells that are shed from a primary tumor into the bloodstream, where they can travel to other sites and possibly establish new tumors. Measuring CTCs could help doctors determine a patient's prognosis and best course of treatment, but these tumor cells are very rare compared with other blood cells, making them difficult to detect. Although some technologies have been developed to identify CTCs in blood, they suffer from limited sensitivity and specificity. Therefore, Zai-Sheng Wu and colleagues wanted to find a way to boost a fluorescent signal for CTCs so that they could be more easily identified.

To develop their method, the researchers chose a breast cancer cell line that, like many breast tumors, produces large amounts of two proteins, ErbB-2 and EpCAM. They isolated the breast cancer cells from a buffer solution with magnetic beads attached to antibodies against ErbB-2. Then, they added a strand of DNA that contained multiple copies of a single-stranded DNA sequence, called an aptamer, that recognizes EpCAM. The strand also carried short DNA sequences that could be used to perform an enzymatic amplification reaction to create many new copies that could bind to fluorescent probes. Using fluorescence spectrometry, as few as nine breast cancer cells could be detected in 200 μL of buffer solution. When the team spiked breast cancer cells into whole blood, they observed a similar fluorescent signal as in the buffer, suggesting that the assay could be a powerful tool for screening rare CTCs in real samples.
-end-
The authors acknowledge funding from the National Natural Science Foundation of China and the Key Project of the Natural Science Foundation of Fujian Province.

The paper's abstract will be available on November 18 at 8 a.m. Eastern time here: http://pubs.acs.org/doi/abs/10.1021/acssensors.0c01082

The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS' mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. The Society is a global leader in providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a specialist in scientific information solutions (including SciFinder® and STN®), its CAS division powers global research, discovery and innovation. ACS' main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.

Follow us: Twitter | Facebook

American Chemical Society

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.